Latest News

The human body has a number of innate responses to infection, including COVID-19, that include heating the affected part of the body, or cooling it down. Yale School of Medicine researchers are looking hard at the causes behind both.

Dr. Eric Meffre talks to WTNH News 8 about a current Yale COVID-19 antibody study.

Yale Cancer Center scientists have developed a new cell screening method for agents that alter biologic functions.

Yale a Site for New COVID-19 NIAID Study

On June 3, 2020, nearly 350 industry representatives and academics joined the inaugural Yale Engage webinar series, Facilitating Collaboration to Combat COVID-19. Opening remarks were made by Michael Crair, PhD, the conversation was moderated by Ruth Montgomery, PhD, and the highly informative panelists included Akiko Iwasaki, PhD, Ellen Foxman, MD, PhD, Naftali Kaminski, MD, Carrie Lucas, PhD, Andrew Wang, MD, PhD. If you were unable to attend, or if you missed a portion of the webinar, please find a link to the recording below, along with a PDF of the panelists’ presentations.

Pober and colleagues report that they have identified a key molecular culprit in the slow death of transplanted tissue.

During a 1989 lecture at the Cold Spring Harbor Symposium on Quantitative Biology, Yale School of Medicine professor Charles Janeway, MD, hypothesized the existence of an innate immune system and special receptors on immune cells (currently known as toll-like receptors) that trigger the body's response to infection. Janeway's research later confirmed his insights, providing the foundation of future endeavors exploring the intricacies of the human immune response. New discoveries continue to reveal an exquisitely tuned immune system in which inflammatory responses and healing are initiated and regulated by known and unknown mechanisms.

Single-Cell Analysis and Machine Learning Identify Major Target of SARS-CoV-2 Infection.